Overview
Bioscope AI provides an AI-powered clinical consultant for primary care through a cloud-based, per-patient subscription that integrates with a physician’s EMR and combines medical records with whole genome sequencing, microbiome data, and other omics to generate health insights. The platform acts as a Virtual Colleague: physicians ask questions and receive evidence-based answers, with a synoptic, fighter-jet–style dashboard that shows patient health across 14 body systems in real time. It differentiates itself by delivering real-time multi-omics integration alongside EMR data and a practical decision-support interface designed to keep clinicians up to date with current evidence. Its goal is to help physicians collaborate with AI to shift care from disease treatment to prevention and longevity, improving preventive care and healthy lifespans.
Work here?Claim your company
Simplify's take
What believers are saying
- Updated November 6, 2026, Bioscope still ships products and leadership hires.
- August 2026 additions of Logan Mallory and Jessica Sexton strengthen go-to-market execution.
- Concierge and longevity clinics buy subscriptions directly, creating high-margin recurring revenue.
What critics are saying
- Self-funding caps runway; Bioscope lacks external capital for trials, sales, and compliance.
- Primary-care EMR integration plus genomics workflow can stall adoption through November 2026.
- If outputs miss a diagnosis, physician liability and trust destruction can kill Bioscope.
What makes Bioscope AI unique
- Don Brown’s 2025 self-funded build avoids VC pressure and preserves product focus.
- Helen Messier joined February 2026, adding credibility in longevity medicine and multi-omics.
- April 2026 upgrades fused whole-genome, labs, wearables, and cited AI answers.
Help us improve and share your feedback! Did you find this helpful?